Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Muscle Spasticity Pipeline Insight

DelveInsight’s, “Muscle Spasticity – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Muscle Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Muscle Spasticity Understanding

Muscle Spasticity: Overview

Spasticity is a condition in which muscles stiffen or tighten, preventing normal fluid movement. The muscles remain contracted and resist being stretched, thus affecting movement, speech and gait. Spasticity is generally caused by damage or disruption to the area of the brain and spinal cord that are responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place. Spasticity can be harmful to growing children as it can affect muscles and joints. People with brain injury, spinal cord injury, cerebral palsy or multiple sclerosis can have varying degrees of spasticity. Symptoms of spasticity can vary from being mild stiffness or tightening of muscles to painful and uncontrollable spasms. Pain or tightness in joints is also common in spasticity. Due to the varying degrees of spasticity, diagnosis may not be so simple. A physical examination with neurological testing will be done to test for spasticity and the severity of it. Imaging such as magnetic resonance imaging (MRI) can provide more information on the source of spasticity and the extent of the damage that has caused it. Many medications are used to treat spasticity, including: botulinum toxin: injected directly into spastic muscles, baclofen: muscle relaxant, diazepam: sedative, phenol: nerve blocker, and tizanidine: calms spasms and relaxes tight muscles.


"Muscle Spasticity - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Spasticity pipeline landscape is provided which includes the disease overview and Muscle Spasticity treatment guidelines. The assessment part of the report embraces, in depth Muscle Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Muscle Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Muscle Spasticity.

Muscle Spasticity Emerging Drugs Chapters

This segment of the Muscle Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Muscle Spasticity Emerging Drugs


Arbaclofen ER: Osmotica Pharmaceuticals

Osmotica Pharmaceutical plc is developing arbaclofen (the active R-enantiomer of baclofen) ER tablets for the treatment of spasticity in patients with MS. This program aims to demonstrate the clinical efficacy and safety of arbaclofen ER tablets in patients with spasticity due to MS. the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking approval for the investigational agent arbaclofen extended release (""ER"") tablets to treat spasticity resulting from multiple sclerosis. The Company intends to review the CRL with its advisors and to request a meeting with the FDA to discuss their recommendations.

Further product details are provided in the report……..

Muscle Spasticity: Therapeutic Assessment

This segment of the report provides insights about the different Muscle Spasticity drugs segregated based on following parameters that define the scope of the report, such as:

  • Major  Players in Muscle Spasticity

There are approx. 8+ key companies which are developing the therapies for Muscle Spasticity. The companies which have their Muscle Spasticity drug candidates in the most advanced stage, i.e. Preregistration include, Osmotica Pharmaceuticals.


DelveInsight’s report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Muscle Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscle Spasticity: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Spasticity therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle Spasticity drugs.

Muscle Spasticity Report Insights

  • Muscle Spasticity Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Muscle Spasticity Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Muscle Spasticity drugs?
  • How many Muscle Spasticity drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle Spasticity?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscle Spasticity therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Muscle Spasticity and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Muscle Spasticity: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Arbaclofen ER: Osmotica Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical stage products

  • Comparative Analysis

MPH-220: Motor Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Muscle Spasticity Key Companies

Muscle Spasticity Key Products

Muscle Spasticity- Unmet Needs

Muscle Spasticity- Market Drivers and Barriers

Muscle Spasticity- Future Perspectives and Conclusion

Muscle Spasticity Analyst Views

Muscle Spasticity Key Companies


List of Table

Table 1: Total Products for Muscle Spasticity

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Muscle Spasticity

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Ipsen Limited
• Revance Therapeutics
• BetterLife Pharma
• Ethicann Pharmaceuticals
• Motorpharma
• Neurana Pharmaceutials
• Vitality Biopharma
• Arbaclofen ER
• Supernus Pharmaceuticals


Forward to Friend

Need A Quote